Pulmonary Embolism | A Pipeline Analysis Report 2018 | Technavio
LONDON--(BUSINESS WIRE)--Technavio has announced its latest pipeline analysis report on the pulmonary embolism market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat pulmonary embolism.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME ONLY: VIEW MARKET SNAPSHOT BEFORE PURCHASING
Pulmonary embolism: Market overview
Pulmonary embolism describes the blockage of a pulmonary artery because of blood clots that travel to the lungs from other parts of the body. It occurs due to deep vein thrombosis, which occurs because of injury and inactivity. Some of the symptoms of pulmonary embolism include irregular heartbeat, anxiety, chest pain, weak pulse, and confusion.
According to a senior market research analyst at Technavio, According to a research, in the US, approximately 900,000 people are affected by pulmonary embolism every year. Around 60,000 to 100,000 Americans die due to pulmonary embolism every year. In addition, 10% to 30% of people die within one month of diagnosis. Around 5% to 8% of the US population has one of the several genetic risk factors, in which a genetic defect can be identified that increases the risk of pulmonary embolism.
Pulmonary embolism: Segmentation analysis
This market research report segments the pulmonary embolism market based on therapies employed including monotherapy, RoA (oral, intravenous, parenteral, inhalation, and unknown), therapeutic modalities (small molecule, biological, and unknown), targets for drugs under development (factor Xa, vitamin K, TAFla, right ventricular, plasminogen, direct thrombin, and tissue plasminogen), MoA (factor Xa inhibitor, vitamin K-antagonist, TAFla inhibitor, pulmonary vasodilation, plasminogen activator, direct thrombin inhibitor, and tissue plasminogen activator ), and recruitment status (recruiting, active not recruiting, not yet recruiting, NA, and unknown).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, all the molecules that are being investigated for the treatment of pulmonary embolism are monotherapy.
In case of oral RoA, the delivery of the drug substances is done through the mouth cavity. About six of the total molecules that are in the current pipeline are expected to be administered orally.
LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST A FREE SAMPLE REPORT
Technavios sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Recruitment volume
- Type of players
- Company Overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at [email protected].